2024 AIM Physician and Investigator Conference

May 18 – 19, 2024 – Boston, Massachusetts

Schedule

All times shown in Eastern Daylight Time (EDT). Time Zone Converter

The Conference Program is available for virtual guests

FRIDAY, MAY 17, 2024

17:00
Guided walking tour of Boston area
19:00
Welcome Reception

SATURDAY, MAY 18, 2024

7:15
Registration & Breakfast
8:00
Mariana Castells – Brigham and Women’s Hospital, Harvard University
Jason Gotlib – Stanford University
Welcome
8:05
Melody Carter – National Institutes of Health
K. Frank Austen Lifetime Achievement Award presented to Dean Metcalfe
8:15
Dean Metcalfe – National Institute of Allergy and Infectious Diseases
K. Frank Austen Lifetime Achievement Award lecture
8:35
Peter Valent – Medical University of Vienna
Diagnosis and classification of mast cell diseases: 2024 status update
SESSION 1: Research Updates in Mast Cell Biology
8:55
Gregor Hoermann – Munich Leukemia Laboratory
Michael Deininger – Versiti Blood Research Institute
Session Chairs
9:00
Karin Hartmann – University of Basel
Soluble biomarkers in indolent and advanced systemic mastocytosis and its implications for novel therapeutic strategies
9:25
Dan Dwyer – Brigham and Women’s Hospital, Harvard University
Progenitor proliferation and mast cell hyperplasia
9:45
Michael Deininger – Versiti Blood Research Institue
Single cell and RNA sequencing in advanced systemic mastocytosis
10:05
Joshua Boyce – Brigham and Women’s Hospital, Harvard University
Mast cell lipid mediators associated to Th2 inflammation
10:25
Gregor Hoermann – Munich Leukemia Laboratory
TNFa as major mast cell soluble cytokine
10:45
Session Chairs
Discussion panel w/ Q&A
10:55
BREAK
SESSION 2: Pathology and Molecular Biology
11:10
Olga Pozdnyakova – University of Pennsylvania
Andreas Reiter – University Hospital Mannheim, Heidelberg University Mannheim, Germany
Session Chairs
11:15
Peng Li – ARUP Laboratories / University of Utah
Clonal hierarchy of myeloid gene mutations in advanced systemic mastocytosis
11:35
Alberto Orfao – University of Salamanca
Altered immune profiles in blood of systemic mastocytosis patients
11:55
Irina Maric – National Institutes of Health
Targeted next-generation sequencing reveals increased incidence of somatic myeloid mutations in pediatric systemic mastocytotis
12:15
Tracy George – ARUP Laboratories / University of Utah
Histopathology of progression in patients with advanced systemic mastocytosis on avapritinib
12:35
Session Chairs
Discussion panel w/ Q&A
12:45
LUNCH
Special Session: The Role of Transplant in Advanced Systemic Mastocytosis
13:30
Deepti Radia – Guy’s and St. Thomas’ Hospitals
Session Chairs
13:35
Andreas Reiter – University Hospital Mannheim, Heidelberg University Mannheim, Germany
Celalettin Ustun – Rush University
Clinical case discussion
SESSION 3: Mast Cell Activation and hereditary alpha tryptasemia
13:50
Pedro Giavina Binachi – University of Sao Paolo
Larry Schwartz – Virginia Commonwealth University
Session Chairs
13:55
Jenny Huang – Scripps College
Tryptase and hereditary alpha tryptasemia in postural orthostatic tachycardia syndrome
14:15
Matthew Giannetti – Brigham and Women’s Hospital, Harvard University
Secondary mast cell activation
14:35
Jonathan Lyons – University of California San Diego
Promoter of alpha tryptase and clinical impact
14:55
Mariana Castells – Brigham and Women’s Hospital, Harvard University
Impact of tyrosine kinase inhibition on urinary mast cell mediators in indolent systemic mastocytosis
15:15
Session Chairs
Discussion panel w/ Q&A
15:25
Poster Walk & Coffee Break
Oral Abstract Presentations
15:55
Thanai Pongdee – Mayo Clinic, Rochester
Cecilia Arana Yi, Phoenix – Mayo Clinic
Session Chairs
16:00
Clayton H. Rische – University of Chicago
Selective depletion of mast cells in mice via Siglec-6 targeted nanotherapy
16:15
Mariana Castells – Brigham and Women’s Hospital, Harvard University
Analysis of hereditary alpha tryptasemia and association with baseline characteristics in patients with indolent systemic mastocytosis enrolled on the PIONEER Study
16:30
Nicole Case – Harvard University
Transcriptomic and phenotypic characterization of mast cell heterogeneity and KIT D816V inhibition in systemic mastocytosis
16:45
Mariana Castells – Brigham and Women’s Hospital, Harvard University
Day One Closing Remarks
18:30
Conference Dinner (Registration Required)

SUNDAY, MAY 19, 2024

7:45
Breakfast
Special Session: Multidisciplinary Interactive Tumor Board
8:30
Matthew Hamilton – Brigham and Women’s Hospital, Harvard University
Session Chairs
8:35
Serine Avagyan – University of California San Francisco
Case #1
8:55
Wesley Roberts – University of Utah
Case #2
9:15
Tara Ballouz – Mayo Clinic, Arizona
Case #3
Session 4: Clinical Heterogeneity in Mast Cell Disease
9:35
Celalettin Ustun – Rush University
Nives Zimmermann – University of Cincinnati
Session Chairs
9:40
Ivan Alvarez Twose – Castilla La Mancha University
Predictive algorithms of systemic mastocytosis
10:00
Jennifer Nicoloro-SantaBarbara – Brigham and Women’s Hospital, Harvard University
Brain impact in mastocytosis
10:20
Melody Carter – National Institutes of Health
Management of unusual cases in pediatric-onset mastocytosis
10:40
Session Chairs
Discussion panel w/ Q&A
10:50
BRUNCH
Session 5: Therapies, Novel Agents, & Survival
11:35
Stephanie Lee – University of Toronto
Tsewang Tashi – University of Utah Huntsman Cancer Center
Session Chairs
11:40
Tsewang Tashi – University of Utah Huntsman Cancer Center
Advanced systemic mastocytosis
12:00
Sudipto Mukherjee – Cleveland Clinic
Decreased survival among patients with indolent systemic mastocytosis
12:20
Thanai Pongdee – Mayo Clinic, Rochester
Indolent systemic mastocytosis: Targeted versus symptomatic treatment approach
12:40
Session Chairs
Discussion panel w/ Q&A
12:50
BREAK
Session 6: Mast Cell Biology and Pre-Clinical Development
13:05
Nathan Boggs – Uniformed Services University
Session Chairs
13:10
Mark C. Siracusa – Rutgers University
CAR1 and proliferation in mast cells
13:30
Marianna Kulka – University of Alberta
Mast cells activiation through MRGPRX2
13:50
Adrian M. Piliponsky – Seattle Children’s Research Institute
Elucidating and targeting Siglec-9 function on mast cells
14:10
Glenn Cruse – North Carolina State University
Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for mast cell disease
14:30
Session Chairs
Discussion panel w/ Q&A
14:40
Mariana Castells – Brigham and Women’s Hospital, Harvard University
Jason Gotlib – Stanford University
Closing Remarks

Accreditation: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Utah and American Initiative in Mast Cell Diseases. The University of Utah is accredited by the ACCME to provide continuing medical education for physicians.

AMA Credit: The University of Utah School of Medicine designates this live activity for a maximum of 13.00 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Passport:
The CME credits that physicians earn from this activity will be submitted to ACCME’s CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Please contact UUCME (CME.Office@hsc.utah.edu) with any questions.

All attendees are encouraged to use the CME system to claim their attendance.  Physicians will be awarded AMA PRA Category 1 credits TM; all other professions will be awarded attendance at a CME event credit that they may use for their re-credentialing purposes. Nurses seeking contact hours must claim through the CME system.  All users will be able to print or save certificates.  For questions regarding the CME system, please contact the UUCME Office.  For questions regarding re-credentialing process or requirements, please contact your re-credentialing organization.

Nondiscrimination and Disability Accommodation Statement: The University of Utah does not exclude, deny benefits to or otherwise discriminate against any person on the basis of race, color, national origin, ethnicity, sex, disability, age, veteran’s status, religion, gender identity, gender expression, pregnancy or pregnancy-related conditions, genetic information, or sexual orientation in admission to or participation in its programs and activities.  Reasonable accommodations will be provided to qualified individuals with disabilities upon request, with reasonable notice.  Requests for accommodations or inquiries or complaints about University nondiscrimination and disability/access policies may be directed to the Director, OEO/AA, Title IX/Section 504/ADA Coordinator, 383 University Street, Level One OEO Suite, Salt Lake City, UT 84112, 801-581-8365 (Voice/TTY), 801-585-5746 (Fax).